Perspective Therapeutics, Inc. (CATX) reported a full‑year 2025 net loss of $103.1 million, or $1.40 per share, compared with a $79.3 million loss ($1.23 per share) in 2024. The widening loss reflects the company’s continued investment in its three clinical‑stage programs and the high‑burn nature of a targeted alpha‑therapy developer.
Operating expenses rose 24% to $114.4 million, driven by a 102% increase in research and development spending to $84.2 million and a 14% rise in general and administrative costs to $30.2 million. The sharp rise in R&D is attributable to expanded clinical site activities, higher drug‑product and delivery costs, and the in‑house hiring of additional personnel. The modest increase in G&A reflects higher personnel costs offset by a reduction in professional‑services fees.
Cash, cash equivalents and short‑term investments stood at $145 million at year‑end, down from $227 million in 2024. A February 2026 underwritten offering raised $164 million in net proceeds, which, combined with the existing cash, is expected to fund clinical milestones and operational needs through late 2027. Prior to the financing, the company’s cash runway would have ended in late 2026.
Grant revenue fell 40% to $0.9 million, a decline from $1.5 million in 2024, reflecting a strategic shift away from NIH‑funded research toward internally prioritized programs. The company also recorded a $10.0 million non‑cash impairment loss for a preclinical asset, contributing to the year‑end operating expenses.
Operating losses of $73.7 million were recorded for the first nine months of 2025, underscoring the high‑burn profile of a clinical‑stage biopharma. Management emphasized that the company’s pipeline progress and the recent financing provide a critical buffer for upcoming data readouts expected in 2026.
CEO Thijs Spoor noted in a November 2025 update that “the strength of our clinical data continues to validate our technology and reinforce our mission to redefine cancer treatment. With several important milestones ahead, we look forward to sharing new data and strategic updates as we close out the year and head into 2026 and beyond.” The company’s focus remains on advancing its Lead‑212 platform across three programs—VMT‑α‑NET, VMT01, and PSV359—while expanding manufacturing capacity in Iowa, New Jersey, and planned sites in Houston, Chicago, and Los Angeles.
Investors responded positively to the February 2026 equity offering, which extended the company’s cash runway to late 2027 and reinforced confidence in its ability to fund the next phase of clinical development. The financing also mitigated the immediate cash‑burn risk that has historically pressured the company’s operating metrics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.